ArQule Message Board - Msg: 9097726

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. Voodoo who wrote (329)	4/23/1999 8:14:00 AM
From: Dr. John M. de Castro	Read Replies (1) of 399

Dr.Voodoo thanks for the thoughtful post. Along the same lines as your ideas, I read in Biocentury a quote from Patrick Gage, President of Wyeth-Ayerst. "We needed access to combinatorial chemistry and the best way to get it was to bring in their (ArQule) combinatorial chemistry technology for small molecules. Other companies might build their own combichem technology, which we will do eventually - you have to, it's a core competency in the industry. Companies that provide these platforms do it more efficiently for a time, but the window doesn't last forever." The implications here are clear. I remember a small bicycle company whose motto was "Inovate or Perish". IMO that applies to ARQL. They have to keep ahead of everyone else to keep the combichem business. So, their heavy investment in R&D may be the best and only route for ARQL to stay ahead. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next